Univariate analysis of clinical outcome for the study population according to Bcl-6 expression and induction treatment
. | CHOP . | . | . | R-CHOP . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical outcome . | Bcl-6+ . | Bcl-6- . | P* . | Bcl-6+ . | Bcl-6- . | P* . | ||||
| No. of patients | 68 | 24 | NA | 86 | 21 | NA | ||||
| Objective response, CR + PR, no. (%) | 51 (75) | 19 (79) | .8 | 70 (81) | 18 (86) | .8 | ||||
| 2-y survival including MR, %† | ||||||||||
| FFS | 61 ± 6 | 38 ± 10 | .004 | 64 ± 5 | 75 ± 10 | .6 | ||||
| OS | 73 ± 5 | 42 ± 10 | .001 | 74 ± 5 | 76 ± 9 | .7 | ||||
| 2-y survival, removing effect of MR, %‡ | ||||||||||
| FFS | 54 ± 6 | 9 ± 6 | < .001 | 58 ± 6 | 76 ± 9 | .2 | ||||
| OS | 77 ± 5 | 17 ± 8 | < .001 | 71 ± 5 | 79 ± 8 | .2 | ||||
. | CHOP . | . | . | R-CHOP . | . | . | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| Clinical outcome . | Bcl-6+ . | Bcl-6- . | P* . | Bcl-6+ . | Bcl-6- . | P* . | ||||
| No. of patients | 68 | 24 | NA | 86 | 21 | NA | ||||
| Objective response, CR + PR, no. (%) | 51 (75) | 19 (79) | .8 | 70 (81) | 18 (86) | .8 | ||||
| 2-y survival including MR, %† | ||||||||||
| FFS | 61 ± 6 | 38 ± 10 | .004 | 64 ± 5 | 75 ± 10 | .6 | ||||
| OS | 73 ± 5 | 42 ± 10 | .001 | 74 ± 5 | 76 ± 9 | .7 | ||||
| 2-y survival, removing effect of MR, %‡ | ||||||||||
| FFS | 54 ± 6 | 9 ± 6 | < .001 | 58 ± 6 | 76 ± 9 | .2 | ||||
| OS | 77 ± 5 | 17 ± 8 | < .001 | 71 ± 5 | 79 ± 8 | .2 | ||||
Median follow-up among all patients is 3.4 years.
NA indicates not applicable.
P values are from the Fisher exact test for objective response rate and log-rank test for FFS and OS.
Analysis includes patients who were randomized to receive MR. Value is 2-year estimated percent ± the SE of the 2-year estimate.
Analysis removes the effect of MR on induction comparison and obtains an unbiased effect of induction treatment. Value is 2-year estimated percent ± the SE for the 2-year estimate.